Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 30 versus LAMICTAL ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 30 versus LAMICTAL ODT.
DILANTIN-30 vs LAMICTAL ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium channel inactivation, thereby inhibiting repetitive firing of action potentials.
Lamotrigine is a triazine derivate that stabilizes presynaptic neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting the release of excitatory neurotransmitters (e.g., glutamate). This suppresses neuronal hyperexcitability and prevents seizure spread.
300 mg/day orally in 3 divided doses (100 mg three times daily) or 300 mg/day once daily as an extended-release capsule. Loading dose: 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) given at 2-hour intervals. Intravenous fosphenytoin loading dose: 15-20 mg PE/kg; maintenance: 4-6 mg PE/kg/day IV.
Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg daily every 1-2 weeks; maintenance 100-200 mg twice daily (200-400 mg/day). For monotherapy or as add-on in epilepsy and bipolar disorder.
None Documented
None Documented
Terminal elimination half-life averages 22 hours (range 7–42 hours) in adults; dose-dependent due to saturable metabolism (Michaelis-Menten kinetics). At low concentrations, half-life is approximately 10–15 hours; at high concentrations, half-life may exceed 30 hours. Clinical context: steady state achieved in 5–10 days; half-life prolonged in neonates, elderly, and hepatic impairment.
Terminal elimination half-life: 25-39 hours (single dose), 12-22 hours (with enzyme inducers), 30-70 hours (with valproate); clinically relevant for dosing titration to avoid Stevens-Johnson syndrome
Renal: ~70% (primarily as inactive metabolites including p-HPPH glucuronide, with <5% unchanged); Biliary/fecal: ~30% (enterohepatic circulation contributes to biliary excretion of metabolites and a small amount of unchanged drug).
Primarily hepatic metabolism (glucuronidation by UGT1A4); 70-90% excreted renally as metabolites, 2% unchanged; 2-10% fecal
Category C
Category C
Anticonvulsant
Anticonvulsant